LANRAPLENIB - PharmaKB

LANRAPLENIB

Lanraplenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase SYK.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

7 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Systemic lupus erythematosus	D008180	EFO_0002690	M32	—	1	—	—	—	1
Cutaneous lupus erythematosus	D008178	EFO_0003834	L93.1	—	1	—	—	—	1
Sjogren's syndrome	D012859	EFO_0000699	M35.0	—	1	—	—	—	1
Syndrome	D013577	—	—	—	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	LANRAPLENIB
INN	lanraplenib
Description	Lanraplenib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase SYK.
Classification	Small molecule
Drug class	spleen tyrosine kinase (Syk) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1